Non-opioid focus Opportunity to engage hospitals and ambulatory care networks by highlighting Recro’s non-addictive, non-opioid pain management solutions such as injectable meloxicam and Dex-IN for peri-procedural pain, aligning with payer and regulatory emphasis on reducing opioid use.

Hospital manufacturing Leverage Recro’s established 97,000 square foot DEA-licensed manufacturing facility to position as a reliable CMO/CDMO partner for small molecule therapeutics, enabling partnerships with pharma sponsors seeking scalable manufacturing and validation capabilities.

Expanding portfolio Target strategic collaborations around Dex-IN and IV meloxicam to address peri-procedural and acute pain markets, including potential co-development or manufacturing agreements with institutions and biotech companies pursuing non-opioid analgesics.

Public funding Explore opportunities with federal research programs and NIH NCATS collaborations to secure development and manufacturing contracts, leveraging prior contract awards to demonstrate credibility and capacity.

Sustainability edge Highlight Recro’s renewable energy initiatives and ESG leadership to appeal to health systems and pharma partners prioritizing sustainability, potentially unlocking green procurement programs and ESG-aligned contracts.